


BMS-932481

| | |
|--------------------|---|
| Cat. No.: | HY-117957 |
| CAS No.: | 1263871-36-8 |
| Molecular Formula: | C ₂₄ H ₂₄ FN ₇ O |
| Molecular Weight: | 445.49 |
| Target: | γ-secretase |
| Pathway: | Neuronal Signaling; Stem Cell/Wnt |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | |
|--------------------|--|---------------|---------------------------------|---------|------------|-----------------|-----------------|---------|---|
| Description | BMS-932481 is an orally active modulator for γ-secretase, selectively reduce Aβ1-42 and Aβ1-40 production, with IC ₅₀ s of 6.6 and 25.3 nM, respectively ^[1] . | | | | | | | | |
| In Vivo | <p>BMS-932481 (2-30 mg/kg, po, single dose) reduces the levels of Aβ1-42 and Aβ1-40, increases levels of Aβ1-38 and Aβ1-37, without changing overall amounts of Aβ peptides in dog models^[1].</p> <p>BMS-932481 (2.5-15 mg/kg, iv, single dose) exhibits moderate brain penetration with brain-to-plasma ratio and AUC_{brain} to AUC_{plasma} ratio of about 0.23 and 0.6 in Sprague-Dawley rats^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Beague dog model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2-30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>po, single dose</td> </tr> <tr> <td>Result:</td> <td>Reduced levels of Aβ1-42 and Aβ1-40 of 65% with 30 mg/kg dose, increased levels of Aβ1-38 and Aβ1-37 by 1.8 and 5 fold.</td> </tr> </table> | Animal Model: | Beague dog model ^[1] | Dosage: | 2-30 mg/kg | Administration: | po, single dose | Result: | Reduced levels of Aβ1-42 and Aβ1-40 of 65% with 30 mg/kg dose, increased levels of Aβ1-38 and Aβ1-37 by 1.8 and 5 fold. |
| Animal Model: | Beague dog model ^[1] | | | | | | | | |
| Dosage: | 2-30 mg/kg | | | | | | | | |
| Administration: | po, single dose | | | | | | | | |
| Result: | Reduced levels of Aβ1-42 and Aβ1-40 of 65% with 30 mg/kg dose, increased levels of Aβ1-38 and Aβ1-37 by 1.8 and 5 fold. | | | | | | | | |

REFERENCES

[1]. Toyn JH, et al., Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects. J Pharmacol Exp Ther. 2016 Jul;358(1):125-37.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA